The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) purchases TriVerity Test System to evaluate for use in the field Inflammatix receives an initial $1.2 million to cover the first phase of system evaluation, with future phase options worth up to $20.8 million SUNNYVALE, Calif.
, March 25, 2025 /PRNewswire/ -- Inflammatix, a pioneering molecular diagnostics company, today announced the shipment of TriVerityTM cartridges and MyrnaTM instruments to the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to facilitate the differentiation of bacterial infections, viral infections, and non-infectious illness. In the first phase of its agreement with Inflammatix, the JPEO-CBRND, which manages the acquisition, fielding and sustainment of chemical, biological, radiological, and nuclear (CBRN) defense capabilities to the joint force, will assess the viability of TriVerity cartridges and MyrnaTM instruments for field use. The initial shipment, for which Inflammatix is to receive more than $1.
2 million , is part of a JPEO-CBRND contract worth up to $20.8 million if all options are exercised. TriVerity, Inflammatix's flagship product, is a rapid blood test that measures the expression levels of 29 genes involved in the immune response associated with acute infection status and illness severity.
The device, which was cleared for clinical use by the U.S. Food and Drug Administration (F.
